Optimizing gonadotrophin-releasing hormone antagonist protocols

Human Fertility

Volumn 5, Issue 1, 2002, Pages

  Trew, Geoffrey H ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ESTRADIOL BLOOD LEVEL; FERTILIZATION IN VITRO; HEALTH CARE COST; HUMAN; INCIDENCE; INFERTILITY; LUTEAL INSUFFICIENCY; LUTEINIZATION; LUTEINIZING HORMONE BLOOD LEVEL; OVARY HYPERSTIMULATION; OVULATION INDUCTION; OVULATION INHIBITION; PREGNANCY RATE; SIDE EFFECT;

EID: 0036128004     PISSN: 14647273     EISSN: None     Source Type: Journal    
DOI: 10.1080/1464727992000199781     Document Type: Conference Paper

References (18)

1. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotrophin and the gonadotrophin-releasing hormone antagonist Cetrorelix
2. Luteal phase after the use of LHRH agonist and antagonist
3. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?
4. Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer
5. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
6. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
7. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
8. The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilisation and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials
9. Is there a difference in the function of granulosa-luteal cells in patients undergoing in vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
10. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction
11. Gonadotrophin-releasing hormone antagonist protocol: A novel method of ovarian stimulation in poor responders
12. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
13. GnRH antagonist in single dose applications
14. GnRH antagonist in single dose applications
15. A prospective, randomized controlled trial comparing the efficacy of recombinant follicle-stimulating hormone in three different in vitro fertilization protocols
16. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
17. Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone
18. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI